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Sustaining Interferon Induction by 
a High-Passage Atypical Porcine 
Reproductive and Respiratory 
Syndrome Virus Strain
Zexu Ma1, Ying Yu1, Yueqiang Xiao1, Tanja Opriessnig2,3, Rong Wang1, Liping Yang1, 
Yuchen Nan1, Siba K. Samal4, Patrick G. Halbur3 & Yan-Jin Zhang1
Porcine reproductive and respiratory syndrome virus (PRRSV) strain A2MC2 induces type I interferons 
in cultured cells. The objective of this study was to attenuate this strain by serial passaging in MARC-
145 cells and assess its virulence and immunogenicity in pigs. The A2MC2 serially passaged 90 times 
(A2MC2-P90) retains the feature of interferon induction. The A2MC2-P90 replicates faster with a higher 
virus yield than wild type A2MC2 virus. Infection of primary pulmonary alveolar macrophages (PAMs) 
also induces interferons. Sequence analysis showed that the A2MC2-P90 has genomic nucleic acid 
identity of 99.8% to the wild type but has a deletion of 543 nucleotides in nsp2. The deletion occurred  
in passage 60. The A2MC2-P90 genome has a total of 35 nucleotide variations from the wild type, 
leading to 26 amino acid differences. Inoculation of three-week-old piglets showed that A2MC2-P90  
is avirulent and elicits immune response. Compared with Ingelvac PRRS® MLV strain, A2MC2-P90 elicits 
higher virus neutralizing antibodies. The attenuated IFN-inducing A2MC2-P90 should be useful for 
development of an improved PRRSV vaccine.
Porcine reproductive and respiratory syndrome (PRRS) is an economically important swine contagious dis-
ease across the world, which has resulted in an estimated $664 million loss per year to the swine industry in 
the United States alone1. The causative agent of the contagious disease is PRRS virus (PRRSV), a positive-sense 
single-stranded RNA virus of the family Arteriviridae2,3. The main target cells for PRRSV infection of pigs are 
pulmonary alveolar macrophages (PAMs)4. PRRSV propagation in vitro is generally conducted in MARC-145 
cells, derived from MA-104, a kidney cell line of an African green monkey5.
PRRSV appears to inhibit synthesis of type I interferons (IFNs) in pigs, whereas swine transmissible gastroen-
teritis virus (TGEV) and porcine respiratory coronavirus (PRCV) induce high levels of IFN-α 6–8. PRRSV antago-
nizes induction of type I IFNs in both PAMs and MARC-145 cells as infection of the cells in vitro leads to very low 
level interferon-α (IFN-α ) expression6,9,10. Type I IFNs are critical to the innate immunity against viral infections 
and play an important role in activation of the adaptive immune response11,12. Adenovirus-mediated expression 
of IFN-α in pigs leads to reduction in disease signs when the animals were challenged with PRRSV13. Presence of 
the exogenous IFN-α at the time of PRRSV infection alters innate and adaptive immune responses by increasing 
IFN-γ secreting cells and changing cytokine profile in the lung 14 days post-infection14.
An atypical type 2 PRRSV strain A2MC2 induces synthesis of type I IFNs in the cultured cells and replica-
tion of A2MC2 is needed for the IFN induction, whereas PRRSV strains VR-2332, Ingelvac PRRS® MLV, NVSL 
97–7895 and VR-2385 do not induce detectable IFNs15. Experimental infection of pigs with the A2MC2 strain 
leads to earlier onset and higher levels of virus-neutralizing antibodies than the Ingelvac PRRS® MLV vaccine 
strain16. Virus neutralizing antibodies against PRRSV confer protection of pigs against challenge with virulent 
strain17. Passive transfer of PRRSV-neutralizing antibodies in pregnant sows confers sterilizing immunity against 
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reproductive failure induced by virulent strain challenge. Passive transfer with PRRSV-neutralizing antibodies to 
young weaned pigs blocks PRRSV viremia from challenge18.
Despite substantial efforts to control PRRS, no production or vaccination regimen has demonstrated sus-
taining success19,20. This is likely in part due to biosecurity challenges and both antigenic and genomic variations 
among PRRSV isolates, allowing for frequent transmission between pig populations and persistence of the virus 
in infected pigs21. Attenuated live virus vaccines have been commercially available for over two decades, however, 
PRRS remains one of the top challenges for swine producers and outbreaks of PRRS. Therefore, an improved 
vaccine is needed to prevent and control PRRS.
In the present study, the objective was to attenuate the A2MC2 strain in MARC-145 cells by serial passaging 
and assess virulence and immunogenicity of the high passages, as previously moderate virulence of the wild type 
strain was observed in pigs16. Interestingly, the feature of IFN induction of the A2MC2 strain is sustained during 
the serial passaging, as passage 90 of the virus is still capable to induce interferon synthesis. A multi-step growth 
assay of high-passaged A2MC2-P90 virus showed that it propagates faster than the wild type virus with a higher 
virus yield. A pig study indicates that the A2MC2-P90 is avirulent and elicits higher virus-neutralizing antibodies 
than Ingelvac PRRS® MLV vaccine strain. Overall, these results demonstrated that the avirulent A2MC2-P90 
virus retains the feature of IFN induction and should be useful as a candidate for development of an improved 
vaccine against PRRS.
Materials and Methods
Cells and viruses. MARC-1455 and Vero (ATCC CCL-81) cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). CRL-2843 (porcine macrophages, ATCC) 
were cultured in RPMI1640 medium supplemented with 10% FBS. Primary PAM cells were prepared from 
4-8-week-old piglets and cultured in RPMI1640 medium supplemented with 10% FBS22.
PRRSV strain A2MC2, VR-2385 and Ingelvac PRRS® MLV were propagated and titrated in MARC-145 
cells. Virus yields were titrated by 10-fold serial dilutions and presented as the median tissue culture infectious 
dose (TCID50)23. Newcastle disease virus (NDV) strain LaSota carrying the gene of green fluorescence protein 
(NDV-GFP) was propagated and titrated in Vero cells24.
Interferon bioassay. Detection of presence of IFNs in culture supernatant from PRRSV-infected MARC-
145 cells was done as previously described15. Briefly, the supernatant was diluted in DMEM and used to treat 
Vero cells in 96-well plates overnight, followed by inoculation with NDV-GFP. Fluorescence microscopy was 
conducted 24 h after NDV inoculation to observe GFP-positive cells.
Immunofluorescence assay (IFA). PRRSV propagation in MARC-145 cells was detected with IFA 
using an N-specific monoclonal antibody EF1125. The infected cells in 96-well plate were fixed and rinsed with 
phosphate-buffered saline (PBS) pH7.2 before addition of the EF11 antibody. DyLight™ 488 conjugated goat 
anti-mouse IgG (Rockland Immunochemicals Inc., Limerick, PA) was used to detect the EF11 binding to the N 
protein in the infected cells. Observation of N-positive cells was conducted under fluorescence microscopy.
Western blotting. Total proteins in cell lysate samples were separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), followed by transfer to nitrocellulose membrane26. Blotting of the membrane with 
antibodies against RIG-I (Santa Cruz Biotechnology, Inc., Dallas, TX) and tubulin (Sigma-Aldrich Corp, St. Louis, MO) 
was conducted. Horseradish peroxidase-conjugated secondary antibodies (Rockland Immunochemicals Inc.) and 
chemiluminescence substrate were used to reveal specific reactions by the primary antibodies. Chemi-Doc Imaging 
System (Bio-Rad, Hercules, CA) was used to capture the luminescence signal.
RNA isolation, reverse transcription, and real-time PCR. Total RNA was isolated with the TRIzol 
Reagent (Life Technologies Corporation, Carlsbad, CA) following the manufacturer’s instructions. Reverse tran-
scription followed by PCR (RT-PCR) and real-time PCR were conducted to amplify target PRRSV sequences or to 
determine PRRSV RNA level22,27. Detection of ribosomal protein L32 (RPL32) expression in the same sample was 
conducted to normalize the total input RNA. Primers of real-time PCR in this study were previously described28 
and analysis of relative transcript levels was performed by normalization of RPL32 in comparison with controls.
For RT-PCR to determine possible deletions in the nsp2 region of the A2MC2 genome during high passages, 
primers 85nspF3 (5′ CTCGACGAACTCAAAGACC3′ ) and 32nsp2R2 (5′ CTGCGGACGGAGCTGATGTGC3′ ) 
were used to amplify the target fragment with Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher 
Scientific, Pittsburgh, PA).
Plaque assay. A plaque assay in MARC-145 cells was done to compare the growth property of A2MC2 high 
passage with the wild type virus15. Briefly, PRRSV A2MC2 was diluted to 10 and 100 TCID50 per ml and added to 
the monolayer cells in 6-well plates at 1 ml per well. After 2 h incubation at 37 °C, the inoculum was removed and 
3 ml 0.5% agarose overlay containing the complete growth medium was added. The cells were stained at 72 h after 
incubation by addition of 2 ml neutral red mixture with agarose and observed for plaques after further overnight 
incubation.
Virus neutralization assay. Virus neutralization assay was performed on MARC-145 cells to determine 
PRRSV-neutralizing antibodies in pig serum samples16. VR-2332, the prototype of type 2 PRRSV with nucleic acid 
identity of 99.8% to A2MC215, was used as target virus in the assay at 100 TCID50 for each reaction. The starting 
dilution of serum samples was 1:8, followed by 2-fold serial dilutions. IFA with N-specific monoclonal antibody 
EF11 was conducted 24 h after inoculation of the cells. Compared to serum samples from mock-infected pigs, the 
reciprocal of the highest serum dilution that reduced 50% PRRSV replication was counted as the VN titer.
www.nature.com/scientificreports/
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Sequencing. RNA isolation from A2MC2 virions was done for reverse transcription, PCR amplification 
and DNA sequencing by chain-termination method using ABI Genetic Analyzer 3130 (ThermoFisher Scientific, 
Waltham, MA)15. Sequence assembly and analysis was done with LaserGene Core Suite (DNASTAR Inc., 
Madison, WI). The cDNA sequence of the full-length A2MC2-P90 genome has been deposited in to GenBank 
(accession number: KU318406).
Animal study. Two animal studies were conducted after approval by Institutional Animal Care and Use 
Committees (IACUC) of the University of Maryland and Iowa State University according to relevant guidelines 
and policies for the care and use of laboratory animals. The first animal study was to determine the virulence of 
the high passages of A2MC2 virus. Three-week-old PRRSV-negative piglets weighing from 3.2 to 7.5 kg were 
randomly divided into five groups with 4 pigs in each group. The piglets in groups 1 to 4 were inoculated with 1 
ml of PRRSV strains A2MC2-P9, A2MC2-P75, A2MC2-P90, and Ingelvac PRRS® MLV, respectively, at 5 × 105 
TCID50/ml via intranasal (I.N.) inoculation, while group 5 was mock-infected with PBS pH7.2. The I.N. inoc-
ulation was used as PRRSV transmits via respiratory route. The pigs in each group were euthanized on day 14 
post infection (DPI14) by pentobarbital overdose (FATAL-PLUS, Vortech Pharmaceuticals, LTD. Dearborn, MI). 
Visible macroscopic lung lesions and histopathology were scored and recorded as previously described29,30. The 
level of interstitial pneumonia was scored ranging from 0 (absent) to 6 (severe diffuse interstitial pneumonia). 
Scoring of macroscopic and microscopic lung pathology was done in a treatment status-blinded fashion inde-
pendently by two veterinary pathologists (TO, PGH). If results disagreed, they were combined and the average 
was used for further analysis.
The second animal study was conducted to assess the immunogenicity of high passages of A2MC2. 
Three-week-old PRRSV-negative piglets were randomly divided into four groups with 4 pigs in each group. The 
piglets in groups 1 to 4 were inoculated with 1 ml of PRRSV A2MC2-P9, A2MC2-P90, and Ingelvac PRRS® 
MLV, respectively, at 5 × 105 TCID50/ml via intramuscular (I.M.) inoculation, while group 4 was mock-infected 
with PBS pH7.2. The I.M. route is generally used for porcine vaccination. Blood samples were collected weekly. 
The pigs were euthanized on DPI48. To assess the antibody response against PRRSV in the pigs, serum samples 
of DPI35 was tested with a commercial PRRSV ELISA kit (IDEXX PRRS X3 Ab Test; IDEXX Inc., Westbrook, 
MA, USA) according to the manufacturer’s instructions. A sample-to-positive (S/P) ratio greater than 0.4 was 
considered positive.
Statistical analysis. Differences between treatment samples and control were assessed by the Student t-test. 
Differences between two groups for VN antibody titers of individual pigs were analyzed using analysis of variance 
(ANOVA). A two-tailed P-value of less than 0.05 was considered significant.
Results
Serial passaging of A2MC2 in MARC-145 cells. PRRSV strain A2MC2 was subjected to serial passaging 
in MARC-145 cells to minimize previously observed moderate virulence16. The A2MC2 virus was passaged in 
MARC-145 cells for 90 consecutive passages. For each passage, the cells were frozen and thawed three times when 
cytopathic effect (CPE) occurred over 50% of the cells. Virus samples were collected for each passage. IFN bio-
assay results showed that treatment of Vero cells with the supernatnat of A2MC2 passage 90 (A2MC2-P90) even 
at a dilution of 1 to 16 inhibited the replication of NDV-GFP (Fig. 1A). This suggested that A2MC2-P90 retains 
the capacity of IFN induction of the wild type A2MC2.
To confirm IFN induction by strain A2MC2-P90, we performed immunoblotting detection of RIG-I, which 
is upregulated by type I IFNs31. Result showed that the RIG-I level increased in the Vero cells treated with culture 
supernatant from A2MC2-P90-infected MARC-145 cells, whereas no change in RIG-I level was observed in 
cells treated with supernatant from VR-2385-infected cells (Fig. 1B). Compared with treatment of mock-infected 
cells, the treatment with supernatant from A2MC2-P90 infected cells led to 97.8 and 141.5-fold higher RIG-I and 
MDA5 transcript levels, respectively, whereas treatment with supernatant from VR-2385-infected cells had only 
0.9 and 0.7-fold of RIG-I and MDA5 transcript levels, respectively (Fig. 1C).
Growth property determination and plaque assay. A2MC2-P90 was tested in MARC-145 cells for 
growth properties, including a multi-step growth curve and a plaque assay as described previously15. The virus 
yields reached its peak at 72 hours post inoculation (hpi) and were 7.7, 7.9 and 8.0 Log10/ml in TCID50 for the cells 
with inoculum at an MOI (multiplicity of infection) of 0.01, 0.1 and 1, respectively (Fig. 2A). The virus yields for 
the cells inoculated with A2MC2-P90 at an MOI of 0.1 and harvested at 24, 48, 72, 96 and 120 hpi were 6.7, 7.3, 
7.8, 7.6 and 7.2 Log10/ml, respectively, which were significantly higher than the yields from the cells inoculated 
with wild type A2MC2 at an MOI of 0.1: 5.0, 5.7, 5.5, 4.6 and 4.1, respectively. Similar trends and titers of virus 
yields were observed for the samples harvested from the cells with the three different amounts of A2MC2-P90 
inoculation.
A plaque assay was done for A2MC2-P90 and compared with wild type A2MC2. The plaque sizes of 
A2MC2-P90 were 8–10 mm in diameter, much bigger than the wild type A2MC2 palques, which were generally 
3–4 mm in diameter (Fig. 2B). The larger size of plaques produced by A2MC2-P90 is consistent with its higher 
yield compared to the wild type virus.
Sequencing of cDNA of A2MC2-P90 genomic RNA. The virions of A2MC2-P90 were used for RNA 
isolation and RT-PCR. DNA sequencing of the PCR products was done and compared with sequences of wild 
type A2MC2 virus. Variations of nucleotides and derived amino acids in comparison with wild type A2MC2, 
VR-2332 and Ingelvac PRRS® MLV were identified (Supplemental Table 1). The locations of the differences in 
genomic RNA are illustrated in Fig. 3. The A2MC2-P90 genome has a deletion of 543 nucleotides (2994–3536) in 
www.nature.com/scientificreports/
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ORF1a in comparison with wild type A2MC2 virus, leading to a deletion of 181 amino acid residues in hypervar-
iable region of nsp2. Moreover, compared to the wild type, the A2MC2-P90 has 35 nucleotide mutations, among 
which 26 are non-synonymous, leading to 26 amino acid changes (Table 1).
Interestingly, among the 15 unique nucleotides in A2MC2 genome compared with Ingelvac PRRS® MLV 
and VR-233215, 14 remained the same in the A2MC2-P90 genome (Fig. 3). As a result, 5 of the 6 unique amino 
acid residues of A2MC2 compared to the MLV and VR-2332 remained the same in A2MC2-P90. The conserved 
five nucleotides leading to unique amino acids in A2MC2 are nt7621, 9655, 12012, 12972 and 12975 and the five 
unique residues are Ser20 in nsp8/9, Leu13 in nsp10, Gly135 in nsp12, and Val93 and Val94 in GP3. This result 
indicates that the 14 nucleotides in A2MC2 are highly conserved and sustained during the 90 serial passages. It 
also suggests that these 14 nucleotides or their related RNA structures might correlate with the feature of A2MC2 
in IFN induction.
The deletion in ORF1a occurs in passage 60 of A2MC2. Having noticed the deletion in nsp2 of 
A2MC2-P90, we wondered at which passage the deletion occurred. RT-PCR was conducted to amplify a fragment 
spanning the deletion area. The expected sizes of the PCR product are 719 bp for A2MC2-P90 and 1262 bp for 
wild type A2MC2. The PCR products for passage 30, 40 and 50 are the same size as wild type A2MC2, while the 
sizes of passage 70 and 80 are the same as A2MC2-P90 (Fig. 4A). There were two main bands in PCR products of 
passage 60. Therefore, the deletion likely occurred around passage 60. PCR amplification of passage 60 through 
63 showed that the size shift from 1262 bp to 719 bp likely occurred from passage 60 to 61 (Fig. 4B). The size shift 
suggests that mutant virus with the spontaneous deletion appeared to become the main virus quickly.
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Figure 1. A2MC2-P90 induces synthesis of interferons. (A) Interferon bioassay in Vero cells. Dilutions of 
cell culture supernatant of MARC-145 cells infected with A2MC2-P90 (A2P90) or A2MC2-P9 (A2P9) were 
used to treat Vero cells. Treatment with 1000 U IFN-α was included as a control. At 12 h after the treatment, 
the Vero cells were inoculated with NDV-GFP. At 24 h post-inoculation of NDV, the cells were observed under 
fluorescence microscopy. (B) Elevation of RIG-I in Vero cells treated with A2MC2-P90 supernatant. The Vero 
cells were treated with culture supernatant from MARC-145 cells infected with VR-2385 (VR) or A2MC2-P90 
(A2) and harvested 24 and 48 h post treatment for immunoblotting. (C) Treatment with A2MC2-P90 
supernatant leads to elevation of RIG-I and MDA5 expression in Vero cells detected by real-time PCR. Relative 
levels of transcripts are shown in folds in comparison to treatment with supernatant from mock-infected 
MARC-145 cells. Significant difference from treatment with supernatant of mock-infected cells is denoted by 
“*”, which indicates P < 0.05 and “***” for P < 0.001.
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A2MC2-P90 induces interferons in PAM cells. PAMs are the major target cells for PRRSV infection 
in vivo4. To determine if A2MC2-P90 can infect PAMs and induce interferons, we inoculated PAMs with the 
high-passage virus at an MOI of 3. Wild type A2MC2 was included as a control. Interferon bioassay was con-
ducted on CRL-2843 cells, immortalized porcine macrophages that are not susceptible to PRRSV, as reported15. 
Results showed that the supernatant of the A2MC2-P90 infected PAMs induced an antiviral effect in CRL-2843 
cells by blocking the replication of NDV-GFP (Fig. 5A). The supernatant dilutions at 1 to 32 still induced inhibi-
tion of NDV-GFP.
A multi-step growth curve was also done to determine the propagation of A2MC2-P90 in PAM cells. The 
virus yields of PAMs inoculated at an MOI of 0.5 were 4.6, 4.6 and 4.8 Log10/ml 24, 48 and 72 hpi, respectively 
(Fig. 5B). A2MC2-P90 appears to be able to replicate in the primary cells though at low level.
Non-virulence of A2MC2-P90 in vivo. The objective of the serial passaging of A2MC2 was to attenuate the 
strain. To determine the degree of attenuation of the A2MC2-P90, we conducted an animal study by inoculating 
3-week-old PRRSV-negative piglets. A2MC2-P9, A2MC2-P75, and Ingelvac PRRS® MLV were included in the 
animal study for control. Compared with pigs inoculated with A2MC2-P9, the pigs infected with A2MC2-P75 
and A2MC2-P90 had significantly lower macroscopic lung lesion scores, like the MLV-infected pigs and the 
mock-infected control in magnitude (Fig. 6A).
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Figure 2. Growth properties of A2MC2-P90 in MARC-145 cells. (A) Multi-step growth curve of A2MC2-P90 
in MARC-145 cells. The cells were inoculated with A2MC2 virus at a multiplicity of infection (MOI) of 0.01, 
0.1 or 1 per cell. Inoculation of A2MC2-P9 at an MOI of 0.1 was included as a control. Virus yields at different 
time points after inoculation were titrated by an immunofluorescence assay. Error bars represent variation of 
three repeated experiments. “***”Denotes significant difference (P < 0.001) in virus yields between A2MC2-P90 
and A2MC2-P9. (B) Plaque assay in MARC-145 cells. The cells were infected with diluted A2MC2-P9 and 
A2MC2-P90 and overlaid with agarose. Plaques were observed 4 days post-infection and photographed for 
comparison.
VR-2332
MLV
A2MC2
1 4680 10037 11666 14420 15411
A2MC2-P90 Del
2994 3536
Figure 3. Illustration of sequence variation of A2MC2-P90 (GenBank accession number: KU318406) 
in comparison to VR-2332 (GenBank accession number: U87392), MLV (GenBank accession number: 
AF066183) and wild type A2MC2 (GenBank accession number: JQ087873). The top line indicates the 
genomic sequence of VR-2332 and the numbers above the line indicate nucleotide positions in the genome. 
The nucleotide variations in comparison with VR-2332 are indicated by vertical bars. The wide bars indicate 
the unique nucleotides identified earlier for A2MC2 in comparison with VR-2332 and MLV. A deletion 
(Del) in A2MC2-P90 from nt2994 to 3536 is indicated. For a list of non-synonymous nucleotide variations 
in A2MC2-P90 genome compared to wild type A2MC2, please refer to Table 1. For a full list of all nucleotide 
variations in A2MC2-P90 genome compared to wild type A2MC2, VR-2332 and Ingelvac PRRS® MLV, please 
refer to Supplemental Table 1.
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Microscopically, the interstitial pneumonia scores of the pigs infected with A2MC2-P75 and A2MC2-P90 
were significantly lower than pigs infected with A2MC2-P9 (Fig. 6B). Both A2MC2-P75 and A2MC2-P90 groups 
had pathology scores similar to the MLV-infected or mock-infected pigs. All the groups except for A2MC2-P9 
Positionb
Nucleotidec Amino acidd
ProteineA2MC2-P90 A2MC2 A2MC2-P90 A2MC2
1414 G A A T nsp2/TF/N
1568 G A G E nsp2/TF/N
3706 T C S P nsp2/TF/N
5369 C T T I nsp3
6520 A G T A nsp5
7168 A G I V nsp7a
7171 C G H D nsp7a
7606 A G I V nsp8/nsp9
9729 G A A T nsp10
10122 G A V I nsp10
11197 T A F Y nsp11
12361 G A V M GP2a
12613 G A V I GP2a
13011 A G S G GP3
13264 T C L S GP3
13367 G A G S GP4
13409 A G N D GP4
13475 A G I V GP4
13798 T A I K GP5
D E GP5a
14026 T G V G GP5
14344 T C V A GP5
15219 G A A T N
Table 1. List of non-synonymous nucleotide mutations and their derived amino acids in A2MC2-P90 
genome compared to the wild type A2MC2a. aGenBank accession numbers: A2MC2 (GenBank ID: JQ087873) 
and A2MC2-P90 (GenBank ID: KU318406). Some nucleotides locate in ORF overlap regions and result in 
different amino acids in the corresponding ORF. bNucleotide positions are indicated on the left column based 
on A2MC2 genomic sequence. cNucleotides at the indicated the genomic sequence positions are listed. dAmino 
acids derived from the codon of indicated nucleotides are listed. ePRRSV viral proteins corresponding to the 
amino acids derived from the codon of indicated nucleotide positions are listed on the right column.
Figure 4. Identification of the initial A2MC2 passage that carries the nsp2 deletion in genome. (A) PCR 
detection of the nsp2 deletion in A2MC2 passages. The passages P30 to P80 were tested. Wild type A2MC2 (P9) 
was included as a control. The PCR product from the genome without deletion is 1.262 kb and it is 0.719 kb from 
the genome with the nsp2 deletion. (B) Identification of the initial A2MC2 passage that has the nsp2 deletion. 
The passages P60 to P63 were tested.
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had no significant difference from the mock-infected control group. These results suggest that under the study 
conditions, A2MC2-P75 and A2MC2-P90 are avirulent in pigs, like the MLV strain.
A2MC2-P90 elicits higher level virus-neutralizing antibodies than the MLV strain. To assess the 
immunogenicity of A2MC2-P90, we conducted an animal study by inoculating 3-week-old PRRSV-negative pig-
lets with A2MC2-P9, A2MC2-P90, and Ingelvac PRRS® MLV viruses. ELISA result showed that all pigs that were 
inoculated with the PRRSV viruses developed specific antibodies by DPI35, whereas the pigs of mock-infected 
group were all negative (Fig. 7A). The average S/P ratios for the virus-infected groups were over 1.6 for all groups 
without significant difference.
Virus-neutralizing antibody assay was conducted for serum samples of DPI28 to DPI42 based on our previous 
study showing the appearance of VN antibody at DPI2816. All pigs in groups of A2MC2-P9 and A2MC2-P90, 
and three of four in MLV group had detectable VN antibodies at DPI28 (Fig. 7B). The average VN titers of the 
A2MC2-P90 and A2MC2-P9 groups were higher than those in MLV group for DPI28, DPI35 and DPI42 samples. 
The results show that similar to the wild type A2MC2 virus, A2MC2-P90 elicits higher VN antibodies than the 
MLV strain in this study.
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Figure 5. A2MC2-P90 induces IFN synthesis in PAM cells. (A) IFN bioassay in CRL2843 cells, in comparison 
with wild type A2MC2. IFN-α was included as a positive control. (B) Multi-step growth curve in PAM cells. The 
cells were inoculated with A2MC2-P90 at an MOI of 0.5. Virus yields were titrated on MARC-145 cells. Error 
bars represent variation of three repeated experiments.
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Discussion
Interferon induction is a unique characteristic of PRRSV strain A2MC2 as PRRSV strains generally antagonize 
interferon synthesis8,15. Considering the importance of interferons in activating the adaptive immune response, 
this feature may be desired in vaccine development against PRRS. Remarkably, the capability of strain A2MC2 
to induce interferons is sustained after 90 serial passages in MARC-145 cells. Like the wild type virus, the 
high-passage virus also induces interferons in PAM cells. Moreover, the A2MC2-P90 is attenuated shown by its 
non-virulence in pigs and elicits higher virus-neutralizing antibodies.
Sequence comparison showed that 14 of 15 unique nucleotides of A2MC2 in comparison with both VR-2332 
and MLV15 are conserved in the A2MC2-P90 genome. Among the six unique amino acid residues, five are iden-
tical in both wild type A2MC2 and A2MC2-P90 and are located in nsp8/9, nsp10, nsp12 and GP3. These residues 
do not correlate with virulence as the A2MC2-P90 is avirulent. The nsp8 has unknown functions. The nsp9 is 
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Figure 6. Lung lesions in pigs infected with PRRSV A2MC2-P9, A2MC2-P75, A2MC2-P90 and MLV at 14 
days post-infection. Four pigs from each group were necropsied. Mock-infected pigs (PBS) were included as 
controls. (A) Average macroscopic lung lesion scores. Error bars represent standard errors of the scores among 
the four pigs in each group. A2: A2MC2. (B) Average microscopic lung lesion scores. Significant differences 
between the group of A2MC2-P9-infected pigs and each of the rest groups are denoted by “**”, which indicates 
P < 0.01.
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Figure 7. Serological testing of serum samples from pig studies. Four pigs from each group were infected. 
Mock-infected pigs (PBS) were included as controls. (A) ELISA of PRRSV antibodies in serum samples of 35 
days post-infection (DPI). The S/P ratio above 0.4 is considered positive. Error bars represent standard errors 
of the ratios among the four pigs in each group. A2: A2MC2. (B) Virus-neutralization antibody assay against 
PRRSV VR-2332. The virus neutralization (VN) titers are shown as reciprocals of serum dilutions shown VN 
activity. Significant differences between the A2MC2 groups and the group of MLV-infected pigs are denoted by 
*and **, which indicate P < 0.05 and P < 0.01, respectively.
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the RNA-dependent RNA polymerase; nsp10 is the helicase and GP3 is a structural glycoprotein32,33. The nsp12 
induces STAT1 phosphorylation at Ser727 and may contribute to expression of inflammatory genes34. None of 
these genes are known to be involved in the PRRSV antagonizing feature of interferon induction. It is not known 
whether these proteins or the nucleotide-related RNA structures play a role in inducing interferon induction. 
Further studies are needed to address the question.
Compared to the wild type virus, A2MC2-P90 genome has a deletion of 543 nucleotides in nsp2. The deletion 
likely occurred around passage 60 as there were both 719 and 1262 bp bands in the PCR of passage 60, but the 
1262 bp band disappeared in passage 61. It appears that the virus with deletion grows faster and quickly became 
the main virus in passage 61. A2MC2-P90 propagates faster with higher yield in MARC-145 cells than the wild 
type A2MC2. Our results are consistent with an earlier report that the spontaneous nsp2 deletion contributes to 
the faster virus propagation in a different strain in vitro35. However, the nsp2 deletion does not have an effect on 
PRRSV virulence for that strain in vivo.
In addition, A2MC2-P90 has 35 nucleotide differences compared to the wild type virus, scattered through-
out the genome. Nsp9 and nsp10 were found to contribute to fatal virulence of high pathogenic PRRSV strains 
in China36. There are one and three different amino acid residues in nsp9 and nsp10, respectively, between 
A2MC2-P90 and the wild type virus (Table 1). Compared with moderate virulent VR-2332 and its derived aviru-
lent MLV, these residues in the wild type A2MC2 are not unique (Supplemental Table 1), suggesting that their cor-
relation with virulence is unlikely. There is no unique synonymous mutations in nsp9 and nsp10 in A2MC2-P90. 
It is thus unknown which nucleotide mutations contribute to the attenuation of A2MC2, possibly a combined 
effect of the multiple mutations has to be considered. Among the 35 nucleotide mutations of A2MC2-P90 in com-
parison with the wild type A2MC2, only nt13011 is the same as in the MLV but different from VR-2332, leading 
to serine in both A2MC2-P90 and the MLV, and glycine in strains A2MC2 and VR-2332. The significance of this 
one amino acid variation between both moderate virulent strains and their avirulent descendants is not known 
and may need to be investigated.
A2MC2-P90 virus replicates faster in MARC-145 cells by inducing larger plaques and having higher titer 
of virus yield. It appears that A2MC2-P90 virus is less sensitive to the interferons it induces, as it replicates well 
when the cells are inoculated at an MOI of 1, while the wild type replicates poorly at this amount of inoculum15. 
This indicates that A2MC2-P90 virus has been adapted to the cells and may gain the ability to dampen the 
interferon-activated antiviral response.
The animal studies demonstrate that A2MC2-P90 is avirulent and elicits better adaptive immune response 
than the MLV strain. The ELISA result showed that all PRRSV-infected pigs were seroconverted by DPI35. 
The VN test result showed most infected pigs had detectable VN antibodies by DPI28. The pigs infected with 
A2MC2-P90 had higher VN titers than the MLV group. The results indicate that the high passage of A2MC2 
carries similar immunogenicity as the wild type virus.
In conclusion, the attenuation of A2MC2 was accomplished by serial passaging in MARC-145 cells. The 
unique feature of interferon induction in both MARC-145 and PAM cells sustains the 90 serial passaging. 
A2MC2-P90 propagates more vigorously in MARC-145 cells than wild type A2MC2. A2MC2-P90 is avirulent in 
pigs. Sequence analysis shows A2MC2-P90 has a 543-nucleotide deletion in nsp2 and 35 nucleotide mutations 
throughout the genome in comparison to the wild type virus. A2MC2-P90 is avirulent and elicits higher VN 
antibodies than the Ingelvac PRRS® MLV strain. Further characterization of the attenuated virus is warranted for 
development of an improved vaccine against PRRS.
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